Hikal touches roof on signing 10-year multi product deal with leading global pharmaceutical innovator company

05 May 2021 Evaluate

Hikal is currently trading at its upper circuit limit of Rs 313.65, up by 28.50 points or 9.99% from its previous closing of Rs. 285.15 on the BSE.

The scrip opened at Rs. 295.00 and has touched a high and low of Rs. 313.65 and Rs. 295.00 respectively. So far 46191 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 290.95 on 04-May-2021 and a 52 week low of Rs. 97.15 on 12-May-2020.

Last one week high and low of the scrip stood at Rs. 290.95 and Rs. 246.15 respectively. The current market cap of the company is Rs. 3515.92 crore.

The promoters holding in the company stood at 68.77%, while Institutions and Non-Institutions held 6.50% and 24.73% respectively.

Hikal has signed multi-year contract with a leading global pharmaceutical company. This contract entails the development and supply of a portfolio of niche APIs over a period of 10 years. The development will start this year and commercial supplies will commence post successful development and plant commercialisation estimated to be in FY 2024 onwards.

With this deal, Hikal is entering into a niche area of chemistry and products thereby bolstering its Animal Health vertical. Hikal and its customer will be jointly investing at its Panoli, Gujarat site to setup a multipurpose manufacturing asset for manufacturing of these API’s.

Hikal is a leading manufacturer and supplier of API's and intermediates globally.

Hikal Share Price

227.30 -0.35 (-0.15%)
31-Dec-2025 11:56 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1720.95
Dr. Reddys Lab 1266.60
Cipla 1500.25
Zydus Lifesciences 912.60
Lupin 2098.55
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×